Daniel P Notzon1,2, Meredith A Kelly1,2, C Jean Choi3, Martina Pavlicova4, Amy L Mahony1, Daniel J Brooks1, John J Mariani1,2, Frances R Levin1,2. 1. a Division on Substance Abuse , New York State Psychiatric Institute , New York , NY , USA. 2. b Department of Psychiatry , College of Physicians and Surgeons, Columbia University , New York , NY , USA. 3. c Division of Biostatistics , New York State Psychiatric Institute , New York , NY , USA. 4. d Department of Biostatistics , Mailman School of Public Health, Columbia University , New York , NY , USA.
Abstract
BACKGROUND: There are no FDA-approved pharmacotherapies for cannabis use disorders (CUD), despite the evaluation of numerous medications. Notably, chronic dosing of oral naltrexone decreases self-administration of cannabis in human laboratory studies. OBJECTIVES: To test the feasibility of long-acting injectable naltrexone for the treatment of CUD, while obtaining preliminary safety and efficacy data. METHODS:Twelve adult participants (seven male) meeting DSM-IV-TR criteria for cannabis dependence enrolled into an 8-week, open-label pilot study conducted at an academic treatment research clinic. They received 380 mg intramuscular injections of long-acting naltrexone on study day 1 and at the start of study week 5. Outcome measures included percentages of study completers and participants who received the second injection, frequency of adverse events (AEs), and cannabis consumption measured by average daily grams, dollars, and using days per week as measured by timeline follow-back and urine oral delta-9-tetrahydrocannabinol (THC) concentrations. RESULTS: Of the 12 participants enrolled in the study, 9 completed the study and 6 received the second injection. There were no severe AEs but an unexpected AE led to the addition of supportive medications to the protocol. Number of cannabis use days per week significantly decreased over the course of the study (p = .001). Creatinine-corrected urine THC concentrations and average daily cannabis use per study week in grams and in dollars did not decrease over the course of the study. CONCLUSIONS: Long-acting injectable naltrexone is a feasible intervention for CUD worthy of further study in a placebo-controlled, double-blinded randomized clinical trial.
RCT Entities:
BACKGROUND: There are no FDA-approved pharmacotherapies for cannabis use disorders (CUD), despite the evaluation of numerous medications. Notably, chronic dosing of oral naltrexone decreases self-administration of cannabis in human laboratory studies. OBJECTIVES: To test the feasibility of long-acting injectable naltrexone for the treatment of CUD, while obtaining preliminary safety and efficacy data. METHODS: Twelve adult participants (seven male) meeting DSM-IV-TR criteria for cannabis dependence enrolled into an 8-week, open-label pilot study conducted at an academic treatment research clinic. They received 380 mg intramuscular injections of long-acting naltrexone on study day 1 and at the start of study week 5. Outcome measures included percentages of study completers and participants who received the second injection, frequency of adverse events (AEs), and cannabis consumption measured by average daily grams, dollars, and using days per week as measured by timeline follow-back and urine oral delta-9-tetrahydrocannabinol (THC) concentrations. RESULTS: Of the 12 participants enrolled in the study, 9 completed the study and 6 received the second injection. There were no severe AEs but an unexpected AE led to the addition of supportive medications to the protocol. Number of cannabis use days per week significantly decreased over the course of the study (p = .001). Creatinine-corrected urine THC concentrations and average daily cannabis use per study week in grams and in dollars did not decrease over the course of the study. CONCLUSIONS: Long-acting injectable naltrexone is a feasible intervention for CUD worthy of further study in a placebo-controlled, double-blinded randomized clinical trial.
Authors: Ralitza Gueorguieva; Ran Wu; Brian Pittman; Joyce Cramer; Robert A Rosenheck; Stephanie S O'malley; John H Krystal Journal: Biol Psychiatry Date: 2007-01-16 Impact factor: 13.382
Authors: Kevin M Gray; Susan C Sonne; Erin A McClure; Udi E Ghitza; Abigail G Matthews; Aimee L McRae-Clark; Kathleen M Carroll; Jennifer S Potter; Katharina Wiest; Larissa J Mooney; Albert Hasson; Sharon L Walsh; Michelle R Lofwall; Shanna Babalonis; Robert W Lindblad; Steven Sparenborg; Aimee Wahle; Jacqueline S King; Nathaniel L Baker; Rachel L Tomko; Louise F Haynes; Ryan G Vandrey; Frances R Levin Journal: Drug Alcohol Depend Date: 2017-06-10 Impact factor: 4.492
Authors: Mohini Ranganathan; Michelle Carbuto; Gabriel Braley; Jaqueline Elander; Edward Perry; Brian Pittman; Rajiv Radhakrishnan; Richard A Sewell; Deepak C D'Souza Journal: Int J Neuropsychopharmacol Date: 2012-01-16 Impact factor: 5.176
Authors: Margaret Haney; Divya Ramesh; Andrew Glass; Martina Pavlicova; Gillinder Bedi; Ziva D Cooper Journal: Neuropsychopharmacology Date: 2015-04-16 Impact factor: 7.853
Authors: Wilfrid Noel Raby; Kenneth M Carpenter; Jami Rothenberg; Adam C Brooks; Huiping Jiang; Maria Sullivan; Adam Bisaga; Sandra Comer; Edward V Nunes Journal: Am J Addict Date: 2009 Jul-Aug
Authors: Evgeny Krupitsky; Edward V Nunes; Walter Ling; David R Gastfriend; Asli Memisoglu; Bernard L Silverman Journal: Addiction Date: 2013-05-24 Impact factor: 6.526
Authors: Jason P Connor; Daniel Stjepanović; Bernard Le Foll; Eva Hoch; Alan J Budney; Wayne D Hall Journal: Nat Rev Dis Primers Date: 2021-02-25 Impact factor: 52.329